

## Tatva Chintan Pharma Chem Limited Reports Q1FY22 Results

Revenue grew 2x to ₹1,098 Mn on Y-o-Y basis

Profit After Tax at ₹231.46 Mn; growth of 244.95% Y-o-Y

Vadodara, August 16<sup>th</sup>, 2021: Tatva Chintan Pharma Chem Limited. (BSE: 543321, NSE: TATVA, ISIN: INE0GK401011), one of India's leading specialty chemical manufacturing company with a diverse product portfolio, has announced its financial results for the quarter ended June 30<sup>th</sup>, 2021.

### Financial Highlights for Quarter Ended June 30<sup>th</sup>, 2021:

- Total Revenue at ₹1,098.00 million in Q1FY22 as compared to ₹517.00 million in Q1FY21 – growth of 112.38% Y-o-Y.
- EBITDA (incl. other income) at ₹288.01 million in Q1FY22 as compared to ₹105.13 million in Q1FY21 – growth of 173.96% Y-o-Y.
- EBITDA (incl. other income) Margins were at 26.23% in Q1FY22 as compared to 20.33% in Q1FY21 – growth of approx. 590 bps Y-o-Y
- Profit After Tax at ₹231.46 million in Q1FY22 as compared to ₹67.10 million in Q1FY21 – growth of 244.95% Y-o-Y
- Basic and Diluted EPS stood at ₹11.52 for the quarter compared to ₹3.34 in Q1FY21; a growth of 244.9%

**Mr. Chintan Shah, Managing Director of Tatva Chintan Pharma Chem Limited, commented, "It gives me immense pleasure to be reporting our first results post our successful IPO. All the financial metrics including revenue and profitability showed a smart increase compared to the corresponding quarter. Additionally, Tatva Chintan has demonstrated its execution capacity and operational efficiencies by registering robust performance. We will continue to place a focus on creating value for stakeholders by putting emphasis on Green Chemistry and R&D Capabilities. Tatva Chintan's strategically diverse product range, geographic dispersion, solid business model are all credible indicators of strong performance ahead."**

### About Tatva Chintan Pharma Chem Limited:

Tatva Chintan Pharma Chem Limited is a player in the specialty chemicals segment that manufactures a diverse portfolio of structure directing agents ("SDAs"), phase transfer catalysts ("PTCs"), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals ("PASC"). It has 2 manufacturing facilities in the state of Gujarat. The company is India's biggest and only commercial manufacturer of SDAs for zeolites, as well as a major producer of an extensive range of PTCs globally. Apart from customers in India, company also export their products to over 25 countries also have two wholly owned subsidiaries in USA and Europe. The Company is focused on serving various customers across various industries, including the automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavours and fragrances industries.

For more information on Tatva Chintan, please visit: [www.tatvachintan.com](http://www.tatvachintan.com)

### For further details please get in touch with:

**Mahesh Tanna – Chief Financial Officer**

Tatva Chintan Pharma Chem Limited

Tel No.: 75748 48533 / 34

Email: [finance@tatvachintan.com](mailto:finance@tatvachintan.com)

**Krishna Patel/Rahul Thakur**

Christensen Advisory

Tel No.: +91 22 4215 0210

Email: [kpatel@christensenir.com](mailto:kpatel@christensenir.com) / [rthakur@christensenir.com](mailto:rthakur@christensenir.com)